Perrigo Company plc PRGO shares are trading higher after the company announced it will acquire HRA Pharma for $2.1 billion in cash.
"The acquisition of HRA would be the crowning achievement in that transformation. With the addition of HRA and its talented leadership team,
Perrigo would be a consumer self-care global leader that is poised to deliver top tier net sales growth and double-digit EPS growth in the near-term while concurrently expanding margins," said Murray S. Kessler, CEO and President, Perrigo.
Perrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to OTC and later with strategic acquisitions.
Perrigo's stock was trading about 8.9% higher at $45.31 per share at the time of publication. The stock has a 52-week high of $51.10 and a 52-week low of $38.20.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.